JNCI Journal of the National Cancer Institute最新文献

{"title":"Treatment Effect Discrepancy Between PFS and OS in Antibody-Drug Conjugate Trials for Metastatic Breast Cancer: A Meta-Epidemiologic Analysis.","authors":"Luiz Felipe Costa de Almeida, Anelise Poluboiarinov Cappellaro, Mariana Macambira Noronha, Lucas Diniz da Conceição, Lorrany Larisse Costa Rodrigues, Luís Felipe Leite, Rodolfo Garza-Morales, Brenda Ernst, Andreia Cristina de Melo, Jessé Lopes da Silva, Paolo Tarantino, Dario Trapani, Felipe Batalini","doi":"10.1093/jnci/djag324","DOIUrl":"https://doi.org/10.1093/jnci/djag324","url":null,"abstract":"<p><strong>Objective: </strong>The validity of progression-free survival (PFS) as a surrogate for overall survival (OS) in the antibody-drug conjugate (ADCs) era remains uncertain. We evaluated the association between treatment effects on PFS and OS in randomized trials of ADCs for metastatic breast cancer (mBC) and explored the surrogate threshold effect (STE).</p><p><strong>Methods: </strong>PubMed, Embase, Cochrane, and ClinicalTrials.gov were searched for published randomized controlled phase II-IV trials evaluating ADCs in mBC and reporting hazard ratios (HRs) for both PFS and OS. A meta-epidemiological approach was used. The primary metric was the ratio of hazard ratios (rHR = HR_PFS/ HR_OS), with rHR < 1 indicating a larger effect on PFS. Trial-level associations were assessed using weighted linear regression (R²) and Spearman's correlation.</p><p><strong>Results: </strong>Twenty-one trials (n = 21; 18 phase III) evaluating nine ADCs were included. The pooled rHR was 0.79 (95% CI, 0.73-0.86), indicating a larger relative effect on PFS than OS. Numerically, the largest discrepancies were observed in triple-negative disease (rHR 0.72) and trials allowing crossover (rHR 0.71). Concordant statistical significance between endpoints occurred in 76% of the trials, whereas 24% showed a significant PFS benefit without OS improvement. The trial-level association between PFS and OS was moderate (R² = 0.62; ρ = 0.67).</p><p><strong>Conclusion: </strong>Treatment effects on PFS consistently exceeded those on OS, although effect directions were highly concordant between endpoints. These findings provide an exploratory framework to contextualize the relationship between PFS and OS in ADC trials, requiring further validation in diverse clinical settings.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148919773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Has cancer care gotten more expensive over time? It's complicated.","authors":"Ya-Chen Tina Shih, Lei Liu","doi":"10.1093/jnci/djag270","DOIUrl":"10.1093/jnci/djag270","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrating genetic predictors into subsequent breast cancer risk prediction in survivors of childhood cancer.","authors":"Aparna Srinivasan, Jian Wang, Gavriel Matt, Lauren J Mills, Yadav Sapkota, Zhaoming Wang, Tianzhong Yang, Joseph P Neglia, Lucie M Turcotte, Melissa M Hudson, Kirsten K Ness, Gregory T Armstrong, Jinghui Zhang, Leslie L Robison, Xin Zhou, Yutaka Yasui, Cindy Im","doi":"10.1093/jnci/djag306","DOIUrl":"10.1093/jnci/djag306","url":null,"abstract":"<p><strong>Purpose: </strong>Female survivors of childhood cancer are at high risk for developing breast cancer. The contributions of most general population primary breast cancer genetic predictors to this risk have not been explored.</p><p><strong>Methods: </strong>Analyses included females who survived ≥5 years after their childhood cancer diagnosis with available array (N = 2096, subsequent breast cancer [SBC]=218) or whole-genome sequencing (WGS; N = 3292, SBC=101) data from the Childhood Cancer Survivor Study and St. Jude Lifetime Cohort. We computed 99 externally-validated primary breast cancer polygenic risk scores (PRS). Using deep-coverage WGS, ClinVar-annotated pathogenic/likely pathogenic (P/LP) variants in breast cancer susceptibility genes were identified. Cox proportional hazards models assessed associations with SBC risk, adjusting for treatments and genetic ancestry.</p><p><strong>Results: </strong>Among 5388 female survivors (genetic ancestry, European: N = 4,752; African: N = 444; East Asian: N = 192), 319 developed SBC. Most (90.9%) PRSs were nominally associated with SBC risk (P < 0.05), but effect sizes varied substantially. PRSs with superior discriminatory ability had greater genome-wide coverage (e.g., 6.4 million-variant PRS, HR per SD = 1.71, 95% CI = 1.43 to 2.05; P = 4.2x10-9) and 7.7-fold higher odds (P = 7.0x10-4) of including variants in multiple DNA damage repair pathways compared with PRSs with weaker risk associations. Among survivors with WGS, 1.6% carried P/LP variants in clinical testing panel genes, which was associated with a 7.4-fold greater risk (95% CI = 3.16 to 17.19). Including genetic factors improved SBC risk prediction by age 40 (P < 0.001) compared to treatment exposures alone.</p><p><strong>Conclusions: </strong>Externally-validated primary breast cancer genetic susceptibility predictors are relevant for SBC risk prediction and should be prioritized for risk stratification in survivors.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148912108","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer incidence trends among Asian American, Native Hawaiian, and Pacific Islander populations in the United States, 2000-2022.","authors":"Anne-Michelle Noone, Scarlett Lin Gomez, Meg McKinley, Annie Vu, Steve Scoppa, James Todd Gibson, Emma H Schwager, Katherine Lin, Iona Cheng, Katherine Chua, Brenda Y Hernandez, Kohei Miyagi, Salma Shariff-Marco, Mandi Yu","doi":"10.1093/jnci/djag314","DOIUrl":"https://doi.org/10.1093/jnci/djag314","url":null,"abstract":"<p><strong>Background: </strong>Asian Americans (AA), Native Hawaiians, and Pacific Islanders (NHPI), collectively referred to as AANHPI, are heterogeneous populations with varying cancer risks across ethnic groups. Incidence rates and trends are examined for eight AA groups (Asian Indian/Pakistani, Chinese (including Taiwanese), Filipino, Japanese, Kampuchean, Korean, Laotian, and Vietnamese) and three NHPI groups (Native Hawaiian, Guamanian/Chamorro, and Samoan).</p><p><strong>Methods: </strong>Annual cancer incidence from 21 Surveillance, Epidemiology, End Results (SEER) registries and population denominators from 2000-2022 were used to calculate incidence rates and average annual percentage change (AAPC).</p><p><strong>Results: </strong>Among females, top five cancers included breast, lung, colon and rectum (CRC), uterus, and thyroid. Cancer incidence trends for breast and uterus were stable or increasing in most groups (AAPC: 0.68% to 5.29% for breast across ethnic groups; 2.13% to 3.65% for uterus). CRC trends were stable or decreasing (-4.01% to-1.06%), except among Asian Indians/Pakistanis (AAPC: 0.79%). Lung cancer increased among Asian Indians/Pakistanis (2.30%) but decreased among Chinese (-1.96%). Thyroid trends increased among Japanese (1.92%) and Vietnamese (1.35%).Among males, top five cancers included prostate, lung, CRC, liver, and non-Hodgkin lymphoma (NHL). Lung, CRC, and liver trends were stable or decreasing in most groups. Prostate trends increased in most groups (2.12% to 5.03%) but decreased among Laotians (-11.79%), Guamanians/Chamorros (-4.67%) and Samoans (-6.89%). NHL trends increased among Asian Indians/Pakistanis (0.98%) and Chinese (1.12%).</p><p><strong>Conclusions: </strong>A nationwide SEER database for evaluating cancer incidence trends through 2022 in disaggregated AANHPI groups is now available from SEER. It highlights ethnically distinct contemporary patterns relevant to research and cancer control initiatives.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148906066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Re: 'Advance care planning impact on caregivers and end-of-life care in advanced cancer'.","authors":"Fumika Yatabe, Yohei Kishi, Anri Inumaru, Yurika Saito","doi":"10.1093/jnci/djag315","DOIUrl":"https://doi.org/10.1093/jnci/djag315","url":null,"abstract":"","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148891148","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A phase II randomized study of proton therapy vs intensity-modulated radiation therapy in patients with unilateral head and neck cancer.","authors":"Edward Christopher Dee, Noah S Kalman, Daniel J Ma, Scott C Lester, Zhigang Zhang, Daphna Gelblum, Yao Yu, Linda Chen, Sean M McBride, Nadeem Riaz, Boris A Mueller, Achraf Shamseddine, Kaveh Zakeri, Jung Julie Kang, Chiaojung Jillian Tsai, Yingzhi Wu, Dennis Mah, Kevin Sine, Andy Shim, Haibo Lin, Alan Ho, Richard J Wong, Paul B Romesser, Christopher A Barker, Nancy Y Lee","doi":"10.1093/jnci/djag257","DOIUrl":"https://doi.org/10.1093/jnci/djag257","url":null,"abstract":"<p><p>Proton beam radiotherapy (PBRT) offers dosimetric advantages over intensity-modulated radiation therapy (IMRT), but prospective randomized data in the postoperative unilateral head and neck cancer setting remain limited. We conducted a multicenter, randomized phase II trial comparing PBRT and IMRT for patients with resected, well-lateralized head and neck cancers requiring unilateral adjuvant radiotherapy. Adults were randomized 1:1 to receive PBRT or IMRT to 60 Gy (relative biological effectiveness) in 30 fractions, with elective regions treated to 54 Gy. The primary endpoint was clinician-reported acute grade ≥2 oral mucositis through 3 months after radiotherapy. Ninety-eight patients were analyzable (PBRT, n = 54; IMRT, n = 44) with a median follow-up of 27.2 months. Acute grade ≥2 oral mucositis occurred less frequently with PBRT than IMRT (7.4% versus 22.7%, P = 0.03), as did acute grade ≥2 dysgeusia (9.3% versus 31.8%, P = 0.005). Rates of grade ≥3 dermatitis and grade ≥2 dysphagia were similar between groups, and late toxicities were uncommon with no grade 3 events. Patient-reported outcomes mirrored these findings, although confidence intervals were wide. Three-year local control, progression-free survival, and overall survival were high and were no different between arms. These findings indicate that PBRT reduces clinician-graded acute mucosal toxicity compared with IMRT in unilateral postoperative head and neck radiotherapy, in the context of some numerical but not statistically significant differences in patient-reported outcomes. ClinicalTrials.gov: NCT02923570.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":""},"PeriodicalIF":7.7,"publicationDate":"2026-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148887510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A framework to evaluate surrogate endpoints at the trial level: analysis in colorectal cancer.","authors":"Brendan J Chia, Carmen Allegra, Smitha Krishnamurthi, Christopher Lieu, Jonathan M Loree, Qian Shi","doi":"10.1093/jnci/djag088","DOIUrl":"10.1093/jnci/djag088","url":null,"abstract":"<p><strong>Background: </strong>Surrogate endpoints are increasingly used as the basis of cancer drug approvals. A strong association between treatment effects on the surrogate and true endpoint is essential for their validation as reliable endpoints. We assess the current evidence of trial-level surrogacy for colorectal cancer (CRC) endpoints through a novel framework.</p><p><strong>Methods: </strong>We developed a framework to grade the quality of oncology surrogate endpoints in 7 domains of the surrogate relationship: data source quality (A-B); disease setting homogeneity (0-3); uniformness of surrogate and true endpoint definitions (0-3); number of trials evaluated (0-4); and individual- (0-2) and trial-level associations (0-8). We screened PubMed using keywords and medical subject headings terms for meta-analyses published before July 6, 2024, validating surrogate endpoint associations across CRC trials. Two reviewers blindly assessed each article before reaching a consensus score. The main outcomes were framework-derived evidence scores and reported trial-level associations (R2) with overall survival.</p><p><strong>Results: </strong>A total of 18 articles were identified, containing 39 evaluations of 12 unique surrogate endpoints for overall survival. Evidence scores ranged from B6 to A23. Only disease-free survival consistently demonstrated high-quality evidence of trial-level surrogacy (≥A18, median R2 = 0.92). Progression-free survival and objective response rate were low-quality surrogates in metastatic CRC (progression-free survival: B6-A15, median R2 = 0.55; objective response rate: B6-A13, median R2 = 0.33). Other evaluated endpoints were demonstrated to be unreliable surrogates.</p><p><strong>Conclusion: </strong>Disease-free survival shows high-quality surrogacy in stage II-III colon cancer. Endpoints identified in the metastatic setting demonstrate inconsistent surrogacy evidence. Reassessment and identification of new endpoints are warranted, particularly with immunotherapy.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1618-1627"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13549721/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147627872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"RE: Electroacupuncture improves cognitive function and neuropsychiatric symptoms in breast cancer survivors: a pilot randomized controlled trial.","authors":"Pei Shen, Xinqi Chen, Cong Wang, Fu Xu","doi":"10.1093/jnci/djag187","DOIUrl":"10.1093/jnci/djag187","url":null,"abstract":"<p><p>We discuss the authors' conclusion regarding targeted acupoint selection improves neuropsychiatric outcomes. In our view, the conclusions would therefore be more defensible if centered on prespecified between-group contrasts and framed as preliminary evidence of possible point-selection effects.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1769-1770"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148390949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular disease risk after radiotherapy and anthracycline-based chemotherapy for diffuse large B-cell lymphoma.","authors":"Yvonne M Geurts, Suzanne I M Neppelenbroek, Berthe M P Aleman, Cécile P M Janus, Augustinus D G Krol, Dick Johan van Spronsen, Wouter J Plattel, Judith M Roesink, Karijn M S Verschueren, Josée M Zijlstra, Harry R Koene, Marten R Nijziel, Erik C Schimmel, Eva de Jongh, Francisca Ong, Liane C J Te Boome, Rozemarijn S van Rijn, Lara H Böhmer, Bastiaan D P Ta, Hein P J Visser, Eduardus F M Posthuma, Yavuz M Bilgin, Karin Muller, Daphne van Kampen, Jan-Paul de Boer, Cynthia So-Osman, Joost S P Vermaat, Roel J de Weijer, Marie José Kersten, Flora E van Leeuwen, Yolande Appelman, Michael Schaapveld","doi":"10.1093/jnci/djag085","DOIUrl":"10.1093/jnci/djag085","url":null,"abstract":"<p><strong>Background: </strong>Few studies examined treatment-specific long-term risks of cardiovascular diseases (CVD) in diffuse large B-cell lymphoma survivors treated with potentially cardiotoxic radiotherapy and/or chemotherapy with or without rituximab after the 1990s.</p><p><strong>Methods: </strong>Long-term CVD risk was examined in a multicenter cohort comprising 2356 diffuse large B-cell lymphoma survivors who survived at least 5 years and who were treated at ages 15-61 years in 1989-2012. CVD data were acquired from medical records, general practitioners, and disease registries. Observed CVD numbers were compared with expected CVD incidence in the Dutch population to estimate standardized incidence ratios (SIRs) and absolute excess risks (10 000 person-years). Treatment-specific CVD risks were assessed using multivariable Cox regression.</p><p><strong>Results: </strong>During a median follow-up of 14.2 years (IQR = 10.1-18.9 years), 312 survivors were diagnosed with a first CVD at least 5 years after treatment. Compared with the general population, diffuse large B-cell lymphoma survivors had increased risks of heart failure ([HF]; SIR = 3.9, 95% confidence interval [CI] = 3.4 to 4.6; absolute excess risk = 62.8) and cerebrovascular accident (SIR = 1.3, 95% CI = 1.0 to 1.7; absolute excess risk = 9.8), while risk of coronary artery disease was decreased (SIR = 0.7, 95% CI = 0.5 to 0.9; absolute excess risk = -30.9). HF risk was higher among females (SIR = 5.3, 95% CI = 4.2 to 6.5) than males (SIR = 3.2, 95% CI = 2.6 to 4.0, P for heterogeneity < .001), and among survivors aged 40 years and younger at diffuse large B-cell lymphoma treatment (SIR = 10.5, 95% CI = 7.2 to 14.8; P for trend < .001). Exposure to more than 300 mg/m2 doxorubicin was associated with a 2.8-fold (95% CI = 1.7 to 4.5) increased risk of cardiomyopathy or HF, while radiotherapy involving the heart was associated with a 1.9-fold (95% CI = 1.1 to 3.1) increased risk of valvular heart disease.</p><p><strong>Conclusion: </strong>Those surviving at least 5 years after diffuse large B-cell lymphoma have increased risks of developing CVDs, especially HF. Physicians and patients should recognize this risk, and individualized cardiac screening should be considered.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1628-1637"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147512405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast cancer recurrence and mortality among survivors of childhood cancer.","authors":"Cindy Im, Hasibul Hasan, Aparna Srinivasan, Emily Stene, Aaron J McDonald, Chaya S Moskowitz, Tara O Henderson, Gregory T Armstrong, Yutaka Yasui, Rita Nanda, Kevin C Oeffinger, Joseph P Neglia, Anne Blaes, Lucie M Turcotte","doi":"10.1093/jnci/djag005","DOIUrl":"10.1093/jnci/djag005","url":null,"abstract":"<p><p>Childhood cancer survivors are at high risk for developing breast cancer as a treatment-related neoplasm. Their risk for, and survival after, breast cancer recurrence has not been characterized. In this study, female survivors had a 10-year breast cancer recurrence risk of 14% (95% confidence interval [CI] = 10% to 20%) similar to patient controls with sporadic breast cancer matched by age, race, ethnicity, and disease characteristics (n = 201 pairs; P = .62). Among survivors with recurrent breast cancer (n = 68), first breast cancers were largely early stage (0-II: 77%). Nearly half (47%) underwent bilateral mastectomies, with 81% performed before recurrence, predominantly from distant metastases. Survivors' 10-year mortality risk after breast cancer recurrence was 89% (95% CI = 61% to 97%), statistically significantly exceeding patient controls (40%; 95% CI = 16% to 57%; P = .0013), for an adjusted 2.8-fold greater risk. Breast cancer was the leading cause of death in these survivors; the 10-year cause-specific mortality probability was 67% (95% CI = 53% to 83%). Comprehensive investigations of breast cancer recurrence drivers and adverse outcomes in this population are needed.</p>","PeriodicalId":14809,"journal":{"name":"JNCI Journal of the National Cancer Institute","volume":" ","pages":"1753-1757"},"PeriodicalIF":7.7,"publicationDate":"2026-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145917581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}